Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants with Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus with or without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)	Biogen Idec Research Limited	Ongoing	BIIB059	2/3	230LE301	King Faisal Specialist Hospital and Research Center (Riyadh) , King Khalid University Hospital (Riyadh)
An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease	Novartis	Completed	ribociclib / letrozole	3b	CLEE011A2404	NGHA-R , KFSH&RC-R , KFSH , KAMC , NGHA-J , KFMC
" A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer"	Novartis	Completed	LEE011 (Ribociclib)	3	CLEE011E2301	KKUH , KFSH & RC-R , NGHA-R , NGHA-J
Multicenter, open-label, study to evaluate safety,tolerability, pharmacokinetics and, pharmacodynamics of LCZ696 followed by a 52-week randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared with enalapril in pediatric patients from1 month to < 18 years of age with heart failure due to systemic left ventricle systolic dysfunction)	Novartis	Completed	Entresto	3	CLCZ696B2319	KFSH&RC-R , KFSH-D
A Retrospective Observational Non-Interventional Study (NIS) to assess Patient Characteristics and Healthcare Resource Use (HCRU) among COVID-19 Patients Receiving Treatment with Nirmatrelvir; Ritonavir (PAXLOVIDTM) in the Kingdom of Saudi Arabia (KSA)	Pfizer	Ongoing	Paxlovid	4	C4671054	King Faisal Specialist Hospital and Research Center (Riyadh) , King Faisal Specialist Hospital and Research Center (Jeddah) , King Abdulaziz Medical City NG (Riyadh) , King Abdulaziz Medical City NG (Riyadh)
Stroke and High-risk TIAs Outcomes with Reduction of Treatment duration in Emergency Rooms. (SHORTER-Study).	King Faisal Specialist Hospital & Research Centre Riyadh, Saudi Arabia	Ongoing	PLAVIX Clopidogrel 75 MG TABLET	3	1	King Faisal Specialist Hospital and Research Center (Riyadh),King Fahad Medical City (Riyadh),King Faisal Specialist Hospital and Research Center (Jeddah)
A Phase 3, Prospective, Multicenter, Double-blind, Double-dummy, Randomized, Active controlled, Parallel-group, Group-sequential, Adaptive, Event-driven Study to Compare Efficacy, Safety, and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension, Followed by an Open-label Treatment Period With Macitentan 75 mg. (UNISUS)	Actelion Pharmaceuticals Ltd.	Ongoing	Macitentan	3	AC-055-315	King Faisal Specialist Hospital and Research Center (Riyadh),King Fahad Medical City (Riyadh)
AN OPEN-LABEL STUDY IN PEDIATRIC (<18 YEARS OF AGE), SEVERE HEMOPHILIA A PARTICIPANTS (COAGULATION FACTOR ACTIVITY <1%) WITH OR WITHOUT INHIBITORS OR MODERATELY SEVERE TO SEVERE HEMOPHILIA B PARTICIPANTS (COAGULATION FACTOR ACTIVITY ≤2%) WITH OR WITHOUT INHIBITORS COMPARING 12 MONTHS OF HISTORICAL STANDARD TREATMENT TO MARSTACIMAB PROPHYLAXIS	Pfizer	Ongoing	Marstacimab	3	B7841008	King Faisal Specialist Hospital and Research Center (Riyadh),King Fahad Specialist Hospital (Dammam)
Non-Interventional Study of the Change in Joint Health in Adult Patients with Haemophilia A after Switching to Prophylaxis with Turoctocog Alfa Pegol (N8-GP)	NovoNordisk	Ongoing	Turoctocog Alfa Pegol (N8-GP)	4	NN7088-492	King Abdulaziz University Hospital (Jeddah),King Fahad Hospital (Jeddah)
The Efficacy and Safety of Degludec Use for Glycemic Control in Critically Ill Patients: A Prospective Interventional Study	King Faisal Specialist Hospital and Research Center	Ongoing	INSULIN ASPART,INSULIN DEGLUDEC	3	1	King Faisal Specialist Hospital and Research Center (Riyadh)